Institution
The Royal Wolverhampton NHS Trust
Recent research
- Health & MedicineOpen access
Abstract In MAIA (Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus Rd in tran...
- Health & Medicine
Purpose of review The delineation of myositis-specific autoantibody (MSA) subgroups over the past two decades has reframed environmental research in idiopathic inflammatory myopathies (IIMs), making it plausible to examine discrete exposure-phenotype pairings within serologically...
- Health & Medicine
Critical result thresholds and notification practices in clinical laboratories
Laboratory medicine plays an important role in clinical decision-making. The timely notification of results requiring medical attention is therefore essential to ensure patient safety. Since its introduction, the concept of critical result notification has expanded to include bot...
- Health & MedicineOpen access
Abstract In previous analyses of MAIA, daratumumab plus lenalidomide/dexamethasone (D-Rd) significantly improved progression-free survival and overall survival (OS) versus lenalidomide/dexamethasone (Rd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM). We report...
- Health & MedicineOpen access
Borderline breast lesions (B3 lesions, also termed lesions of uncertain malignant potential or high-risk lesions) represent a heterogeneous group of entities associated with variable risks of malignancy. While the management of screen-detected B3 lesions has become increasingly s...